While αSMA has been utilized as a biomarker of LMC coverage that associates with lymphatic function in previous studies23,25,27, other proteins (i.e. myosin heavy chain 11 (Myh11))36 or transcriptional changes (i.e. Zbtb16)22 may have recovered during the treatment period associated with amelioration of arthritis. Here, MYH11 is linked to arthritic joint disease.